Case report: Severe gastrointestinal inflammation and persistent HHV-6B infection in a paediatric cancer patient

Herpes

Volumn 14, Issue 2, 2007, Pages 41-44

  Breddemann, André ^a   Läer, Stephanie ^a   Schmidt, Klaus G ^a   Harjes, Malte ^a   Adam, Rüdiger ^a   Ludwig, Amei ^a   Niehues, Tim ^a   Schneider, Dominik T ^a  

^a HEINRICH HEINE UNIVERSITY   (Germany)

Author keywords

Children; Cidofovir; Foscarnet; Ganciclovir; HHV 6; Immunosuppression; Pharmacotherapy

Indexed keywords

CARBOPLATIN; CIDOFOVIR; CYCLOPHOSPHAMIDE; CYTOMEGALOVIRUS ANTIBODY; ETOPOSIDE; FOSCARNET; GANCICLOVIR; IMMUNOGLOBULIN A; METHOTREXATE; PREDNISOLONE; VINCRISTINE;

ARTICLE; CANCER CHEMOTHERAPY; CANCER PATIENT; CASE REPORT; CD4+ T LYMPHOCYTE; CHILDHOOD CANCER; CLINICAL FEATURE; CORTICOSTEROID THERAPY; CYTOMEGALOVIRUS; DIARRHEA; DIGESTIVE SYSTEM INFLAMMATION; DISEASE SEVERITY; DRUG DOSE ESCALATION; DRUG DOSE REDUCTION; DRUG SUBSTITUTION; DRUG TREATMENT FAILURE; DRUG WITHDRAWAL; FAILURE TO THRIVE; GLIOBLASTOMA; HERPES SIMPLEX; HUMAN; HUMAN HERPESVIRUS 6; HUMAN HERPESVIRUS 6B; IMMUNOGLOBULIN BLOOD LEVEL; INFANT; LOADING DRUG DOSE; LOW DRUG DOSE; LYMPHOCYTOPENIA; MALE; PERSISTENT INFECTION; PRIORITY JOURNAL; VIRUS LOAD;

ANTI-INFLAMMATORY AGENTS; ANTINEOPLASTIC AGENTS; ANTIVIRAL AGENTS; ASTROCYTOMA; CYTOSINE; DIARRHEA; DRUG THERAPY, COMBINATION; GASTROINTESTINAL DISEASES; HERPESVIRUS 6, HUMAN; HUMANS; IMMUNOSUPPRESSION; INFANT; INFLAMMATION; MALE; PHOSPHONIC ACIDS; PREDNISOLONE; ROSEOLOVIRUS INFECTIONS; TREATMENT OUTCOME;

HUMAN HERPESVIRUS 6;

EID: 35048862852     PISSN: 09697667     EISSN: 14701537     Source Type: Journal    
DOI: None     Document Type: Article

References (21)

1. De Bolle L, Naesens L, De Clercq E. Update on human herpesvirus 6 biology, clinical features, and therapy. Clin Microbiol Rev 2005;18:217-245.
2. Clark DA, Griffiths PD. Human herpesvirus 6: relevance of infection in the immunocompromised host. Br J Haematol 2003; 120:384-395.
3. Braun DK, Dominguez G, Pellett PE. Human herpesvirus 6. Clin Microbiol Rev 1997;10: 521-567.
4. Yoshikawa T. Human herpesvirus 6 infection in hematopoietic stem cell transplant patients. Br J Haematol 2004;124: 421-432.
5. Knox KK, Carrigan DR. Disseminated active HHV-6 infections in patients with AIDS. Lancet 1994; 343:577-578.
6. Safdar A, Brown AE, Malkin M. Acute febrile myelodysplasia and pneumonitis due to human herpesvirus 6 after accelerated chemotherapy. Am J Med 2001;111: 329-330.
7. Manichanh C, Grenot P, Gautheret-Dejean A, Debre P, Huraux JM, Agut H. Susceptibility of human herpesvirus 6 to antiviral compounds by flow cytometry analysis. Cytometry 2000;40:135-140.
8. Mace M, Manichanh C, Bonnafous P, Precigout S, Boutolleau D, Gautheret-Dejean A et al. Real-time PCR as a versatile tool for investigating the susceptibility of human herpesvirus 6 to antiviral agents. Antimicrob Agents Chemother 2003;47: 3021-3024.
9. Zerr DM, Gupta D, Huang ML, Carter R, Corey L. Effect of antivirals on human herpesvirus 6 replication in hematopoietic stem cell transplant recipients. Clin Infect Dis 2002;34:309-317.
10. Yoshida M, Yamada M, Tsukazaki T, Chatterjee S, Lakeman FD, Nii S et al. Comparison of antiviral compounds against human herpesvirus 6 and 7. Antiviral Res 1998;40:73-84.
11. Ballauff A, Eggert A. Intraabdominal and hepatic infections in pediatric cancer patients (in German). Klin Padiatr 2005;217:101-109.
12. Schuster FR, Simon A, Laws HJ, Beutel K, Groll AH, Jager G et al. Viral infections in pediatric cancer patients. Klin Padiatr 2005;217:67-84.
13. Boutolleau D, Duras C, Bonnafous P, Caiola D, Karras A, Castro ND et al. Identification of human herpesvirus 6 variants A and B by primer-specific real-time PCR may help to revisit their respective role in pathology. J Clin Virol 2006;35:257-263.
14. Hoffman JA, Shah AJ, Ross LA, Kapoor N. Adenoviral infections and a prospective trial of cidofovir in pediatric hematopoietic stem cell transplantation. Biol Blood Marrow Transplant 2001;7:388-394.
15. Cundy KC, Petty BG, Flaherty J, Fisher PE, Polis MA, Wachsman M et al. Clinical pharmacokinetics of cidofovir in human immunodeficiency virus-infected patients. Antimicrob Agents Chemother 1995;39: 1247-1252.
16. Laer S, Elshoff JP, Meibohm B, Weil J, Mir TS, Zhang W et al. Development of a safe and effective pediatric dosing regimen for sotalol based on population pharmacokinetics and pharmacodynamics in children with supraventricular tachycardia. J Am Coll Cardiol 2005;46:1322-1330.
17. Yamanishi K, Okuno T, Shiraki K, Takahashi M, Xondo T, Asano Y et al. Identification of human herpesvirus-6 as a causal agent for exanthem subitum. Lancet 1988;1:1065-1067.
18. Morford LA, Dix AR, Brooks WH, Roszman TL. Apoptotic elimination of peripheral T lymphocytes in patients with primary intracranial tumors. J Neurosurg 1999;91:935-946.
19. Arno K, Tanaka-Taya K, Inagi R, Miyagawa H, Miyoshi H, Okusu I et al. Human herpesvirus 6B infection of the large intestine of patients with diarrhea. Clin Infect Dis 2003;36:120-123.
20. Ljungman P, Reusser P, de la Camara R, Einsele H, Engelhard D, Ribaud P et al. Management of CMV infections: recommendations from the infectious diseases working party of the EBMT. Bone Marrow Transplant 2004;33:1075-1081.
21. Manichanh C, Olivier-Aubron C, Lagarde JP, Aubin JT, Bossi P, Gautheret-Dejean A et al. Selection of the same mutation in the U69 protein kinase gene of human herpesvirus-6 after prolonged exposure to ganciclovir in vitro and in vivo. J Gen Virol 2001;82:2767- 2776.